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Abstract
Ebola virus is a highly lethal human pathogen and is rapidly driving many wild primate populations toward extinction. Several lines of evidence suggest that innate, nonspecific host factors are
potentially critical for survival after Ebola virus infection. Here, we show that nonreplicating
Ebola virus-like particles (VLPs), containing the glycoprotein (GP) and matrix protein virus protein (VP)40, administered 1–3 d before Ebola virus infection rapidly induced protective immunity.
VLP injection enhanced the numbers of natural killer (NK) cells in lymphoid tissues. In contrast
to live Ebola virus, VLP treatment of NK cells enhanced cytokine secretion and cytolytic activity
against NK-sensitive targets. Unlike wild-type mice, treatment of NK-deficient or -depleted
mice with VLPs had no protective effect against Ebola virus infection and NK cells treated with
VLPs protected against Ebola virus infection when adoptively transferred to naive mice. The
mechanism of NK cell–mediated protection clearly depended on perforin, but not interferon-
secretion. Particles containing only VP40 were sufficient to induce NK cell responses and provide
protection from infection in the absence of the viral GP. These findings revealed a decisive role
for NK cells during lethal Ebola virus infection. This work should open new doors for better understanding of Ebola virus pathogenesis and direct the development of immunotherapeutics,
which target the innate immune system, for treatment of Ebola virus infection.
Key words: virus-like particles • filoviruses • immunity • matrix protein • glycoprotein

Introduction
The filovirus Ebola (Ebola virus) quickly outpaces the innate
immune response of the host and causes an acute, progressive
hemorrhagic fever with mortality rates of up to 90% (1, 2).
The key initiators of innate immunity, including monocytes,
macrophages, and DCs, appear to be the primary targets of
filovirus infection (3–6). Ebola virus replicates efficiently in
DCs without eliciting cytokine and chemokine secretion,
and infected DCs fail to mature and alert other critical mediators of early and adaptive immune responses (5, 6). This
lack of DC activity most likely results in poor immune responses by NK, T, and B cells, which in turn contribute to
the uncontrolled spread and growth of the virus. In conAddress correspondence to Sina Bavari, United States Army Medical
Research Institute of Infectious Diseases, 1425 Porter St., Frederick,
MD 21702. Phone: (301) 619-4246; Fax: (301) 619-2348; email:
sina.bavari@amedd.army.mil
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trast, the early initiation of innate proinflammatory responses
correlates with the survival of Ebola virus–infected humans
(7–10). Therefore, the rapid initiation of early immune
responses may limit Ebola virus infection, and is critically
linked to host survival.
NK cells are key components of the innate immune system,
rapidly responding to invading microbes by exocytosis of
perforin and granzymes, which mediate the destruction of
infected cells (11). Additionally, NK cell secretion of cytokines such as IFN-, IFN-/, and TNF- serve a dual
purpose in that they initiate the immediate activation of
antimicrobial pathways in infected cells, followed by modulation of adaptive responses to the pathogen (11–13). The
Abbreviations used in this paper: GP, glycoprotein; MCMV, murine cytomegalovirus; MIP, macrophage inflammatory protein; moi, multiplicity of
infection; VLP, virus-like particle; VP, viral protein.
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induction of cytokines and chemokines by viral infections
is also known to trigger NK cell activity. Specifically, virusinduced IFN-/ enhances NK cell–mediated cytotoxicity. Alternately, the induction of IL-12 by some viral infections is responsible for the production of high levels of
IFN- by NK cells, as well as the induction of NK cytotoxic activity (11).
NK cells appear to play a critical role in the immune
response to Epstein-Barr virus, murine cytomegalovirus
(MCMV), and herpes simplex virus-1 (14–16). The clinical
importance of NK cells to antiviral immunity is documented
by the fact that recurrent herpesvirus infections have been
observed in a NK-deficient patient (17). NK cell activity is
closely regulated by a myriad of activating and inhibiting cell
surface receptors, and consequently, viruses have evolved
multiple mechanisms to evade or modulate these receptors.
Such mechanisms include the up-regulation of HLA-C and
HLA-E molecules on the surface of virus-infected cells, expression of viral MHC homologues to trigger NK inhibitory
receptors, and/or the release of cytokine homologues with
inhibitory activities (11, 12, 14). In contrast, virus-infected
cells often down-regulate MHC class I on their surface,
which enhances NK cell–mediated lysis due to removal of
the inhibitory signals delivered by the MHC.
There is a limited understanding of the interactions of
the innate immune response and, in particular, NK cell responses to Ebola virus infection. To investigate the role of
early, innate immune responses to Ebola virus, we established a model in the context of the viral proteins, presented as virus-like particles (VLPs). We have shown previously that VLPs, comprised of the Ebola virus glycoprotein
(GP) and matrix protein virus protein (VP)40, efficiently
mature and activate murine myeloid DCs (18). In addition
to their potent activation of DCs, which are critical mediators of innate and adaptive immune responses, VLPs activate T and B cells in vivo after intraperitoneal administration to mice (18). VLPs are highly immunogenic in mice in
the absence of adjuvant and provide a much-needed tool
for safely dissecting immune responses to filoviruses. Therefore, during these investigations, we used the genome-free
Ebola VLPs to study the contribution of NK cells to innate
immune responses to lethal Ebola virus infection.

Materials and Methods
Virus and Cell Lines. The wild-type strain of Ebola virus–
Zaire was originally isolated from a fatally infected human in
1995 (19). The Ebola virus–mouse-adapted strain was generated
by serial passage in progressively older mice (20). Ebola virus was
propagated and viral titers were assessed by standard plaque assay
in Vero E6 cells (19, 20). Inactivated Ebola virus–Zaire 1995
preparations were purified from cell-free supernatants on continuous sucrose gradients and irradiated with 10 7 rad, as described
previously (21). All experiments with Ebola virus were performed under maximum containment in a biosafety level-4 laboratory at the United States Army Medical Research Institute of
Infectious Diseases.
Mice. BALB/c, C57Bl/6, and IFN- –deficient (C57Bl/6
background) mice were obtained from the National Cancer Insti-
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tute. Perforin-deficient (BALB/c background) mice were provided by T. Sayers (National Cancer Institute, Frederick, MD).
NK cell–deficient mice were generated and bred at Washington
University (22). NK cells were depleted from C57Bl/6 mice by
intraperitoneal injection of 50 l of anti-asialoGM antibodies
(Wako Chemicals USA, Inc.) every other day from 5 to 5 d
after challenge. Control mice were treated in the same manner
using rabbit Ig (Sigma-Aldrich). Mice (6–12-wk-old) were divided randomly into experimental groups, housed in microisolator cages, and provided food and water ad libitum. Research was
conducted in compliance with the Animal Welfare Act and other
federal statutes, and regulations relating to animals and experiments involving animals and adhered to principles stated in the
Guide for the Care and Use of Laboratory Animals. The facility
where this research was conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal
Care International.
VLP Preparation. To generate VLPs, 293T cells were cotransfected with pWRG vectors encoding for Ebola virus VP40
and GP (VLP) or Ebola virus VP40 alone (VLP VP40) using Lipofectamine 2000 (Invitrogen). To purify the VLPs, the cell-free
supernatants were harvested after 2–3 d and pelleted at 9,500 g
for 4 h. These crude preparations were separated on a 20–60%
continuous sucrose gradient by ultracentrifugation overnight.
The gradient fractions were concentrated by a second centrifugation, resuspended in endotoxin-free PBS, and the fractions containing the VLPs were determined using Western blots and electron microscopy. As a control, cell-free supernatants from 293T
cells transfected with an empty pWRG vector were purified in an
exact manner as the VLP preparations. Only a very small amount
of cell-free supernatants from mock-transfected cells could be
generated, and experiments with these sucrose-purified supernatants resulted in a similar outcome to medium alone. Therefore,
the sucrose-purified cell-free supernatants were only used in select experiments. The amount of inactivated Ebola virus and VLP
in each preparation was quantitated using a semi-quantitative
Western blot for VP40 along with a measurement of total protein
concentration, obtained by disrupting the samples with NP-40
detergent before use in a detergent-compatible protein assay
(Bio-Rad Laboratories). The VLP preparations used in this work
were 0.03 U/mg endotoxin as determined by the Limulus amebocyte lysate test (Biowhittaker).
VLP Injection and Ebola Virus Challenge of Mice. For protection experiments, mice were injected intraperitoneally or intramuscularly with 25 g of VLP, VLPVP40, inactivated Ebola virus,
or PBS alone 1, 2, or 3 d before challenge with mouse-adapted
Ebola virus. Mice were challenged by intraperitoneal injection. As
noted, mice were injected with 10 or 100 PFU of mouse-adapted
Ebola virus ( 300 or 3,000 LD50, respectively; reference 20).
After challenge, mice were observed at least twice daily for illness
and death for at least 28 d; no changes were observed in the health
of any mice in these studies between 14 and 28 d after infection.
Flow Cytometry. The spleen or mediastinal lymph nodes
were collected from individual mice and placed in RPMI 1640
medium containing 10% FBS, 2 mM l-glutamine, 1 mM Hepes,
and 0.1 mM of nonessential amino acids (referred to as complete
RPMI 1640). Single cell suspensions of lymphocytes were produced from each sample, the red blood cells were lysed with
ACK lysis buffer, and the phenotypic expression of cells was examined by flow cytometry with NK1.1-FITC (BD Biosciences).
Intracellular IFN- in NK cells was detected after fixation and
permeabilization using Cytofix/Cytoperm™ (BD Biosciences),
staining with PE-labeled IFN- , and analysis by flow cytometry
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as described aforementioned. The percent of positive events was
determined after collecting 50,000 events (gated based on forward
and side scatter for viable lymphocytes) per sample using CELLQuest™ software on a FACSCalibur ® (BD Biosciences).
Enrichment and Depletion of NK Cells. NK cells were isolated
from the livers of mice after a hydrodynamic shearing method,
which was used to increase the numbers of NK cells obtained
from each mouse, unless noted otherwise (24, 25). In brief, mice
received a hydrodynamic shear, or rapid tail vein injection, with
5 g IL-2 plasmid in 1.6 ml of 0.9% normal saline. 3–4 d after the
injection, lymphocytes were isolated using a 40–80% Percoll ®
step gradient from perfused livers of the IL-2–treated mice. The
NK cell preparations were obtained by negative selection using
biotinylated CD3, CD4, CD8, and CD19 antibodies (BD Biosciences) followed by streptavidin MicroBeads (Miltenyi Biotec).
The NK preparations were routinely 85–95% pure based on flow
cytometry analysis for cell surface expression of NK1.1, both before and after overnight stimulation. The NK cell–enriched preparations contained 3–10% eosinophils, based on forward and side
scatter and CD11b expression, 1–3% B220 MHC class II DCs,
B cells, and 1–2% CD5 T cells and did not contain CD3  NK
T cells (unpublished data). To deplete the NK cells from the NK
cell–enriched preparations, the cells underwent a second negative selection using biotinylated NK1.1 antibodies (BD Biosciences) and streptavidin magnetic beads (yielded 90% NK cell
depletion).
Cell Stimulations and Blocking Studies. NK cells (106 cells/ml
of complete RPMI 1640) were stimulated for 2–72 h with 100
iU/ml of murine IL-2 (PeproTech), 10 g/ml polyI:C, or 0.1–
50 g of inactivated Ebola virus, VLPs, or sucrose-purified cellfree supernatants from mock-transfected cells. To assess the role
of LPS contamination on NK cell cytokine secretion, 50 g/ml
of VLPs or 10 ng/ml LPS was incubated for 1 h with 100 g/ml
of polymyxin B at room temperature (26) or boiled for 1 h before
their addition to NK cell preparations. In the blocking experiments, 10 g of VLPs were incubated with either a pool of three
mAbs against Ebola virus GP (10 g each; reference 27), 30 g of
an anti-Ebola virus VP40 mAb, 30 l of mouse sera from mice
vaccinated with either a replication-deficient Venezuelan equine
encephalitis particle vaccine (VRP) expressing Ebola VP40 or
Lassa N (a gift of M.K. Hart, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD; reference
28), or 30 g of anti–human CD2 antibody (BD Biosciences).
Percent inhibition of IFN-  secretion was calculated as follows:
[IFN- secretion with test antibody/IFN-  secretion with control antibody (hCD2)] 100%.
Cytotoxicity Assay. A standard 4-h 51Cr assay was used to assess the cytotoxic activity of the stimulated NK cells (29). Varying
numbers of stimulated NK cells were added to 5,000 51Cr-labeled
YAC-1 target cells for 4 h. The amount of 51Cr released into the
supernatants of each sample was determined and the specific lysis
was assessed by: [(sample cpm-spontaneous release)/(total releasespontaneous release)] 100%.
Cytokine Detection. Concentrations of IFN- and TNF-
present in culture supernatants were measured by cytometric
bead array (BD Biosciences) per the manufacturer’s directions.
The concentration of IFN-, macrophage inflammatory protein
(MIP)–1, and TNF- present in the Ebola virus–treated NK
cell supernatants was tested by ELISA (R&D Systems) under biosafety level-4 containment.
NK Cell Transfers. After overnight stimulation, NK cells
106 viable NK cells
were washed twice and enumerated. 5
were resuspended in PBS and injected intraperitoneally into naive
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mice. The recipient mice were challenged 6 h later with Ebola
virus, and illness and survival were scored for 28 d.
Statistical Analysis. A paired Student’s t test was used to directly compare treated and mock-treated samples. The proportion of treated and control animals surviving was compared by
one-tailed Fisher exact tests within experiments. For survival experiments with more than one treatment group, adjustments for
multiple comparisons were made by stepdown Bonferroni correction. Analyses were conducted using SAS Version 8.2 (SAS
Institute Inc.). A p-value of 0.05 was considered significant.

Results
VLPs Rapidly Induce Protection from Lethal Ebola Virus Infection. Morphologically, VLPs are almost indistinguishable from inactivated Ebola virus by electron microscopy
(18, 23) or by atomic force microscopy (Fig. 1 A and reference 2). The VLPs induced potent innate immune re-

Figure 1. Ebola VLPs induce
rapid protective responses against
Ebola virus infection. (A) Atomic
force micrograph of a VLP,
courtesy of M. Thompson (Veeco
Instruments, Woodbury, NY).
Bar, 0.25 m. (B) C57Bl/6 mice
were primed intraperitoneally
with 25 g of VLPs () 1 d (n
10), () 2 d (n 10), or () 3 d
(n
30) before challenge; ()
irradiated, inactivated Ebola virus
(n
10); () sucrose-purified
supernatants from mock-transfected cells or PBS (n 30) 3 d
before challenge with 100 PFU
of mouse-adapted Ebola virus.
Results are plotted as percent
survival for each group, and the
survival curves were constructed
using data from two to five separate experiments. Treatment with
VLPs 1–3 d before challenge significantly increased the proportion of the mice surviving challenge (P  0.0001) compared
with mice treated with Ebola virus
infection or sucrose-purified supernatants from mock-transfected
cells, based on a one-way Fisher’s
exact test. (C) One intramuscular
injection with () VLPs or ()
PBS was administered to C57Bl/6
mice (n 10/group) 3 d before
challenge with 100 PFU of
mouse-adapted Ebola virus. Results are plotted as percent survival for each treatment group.
The data were generated in two
separate experiments with five
mice per group. A significant increase in survival was observed in VLPtreated mice compared with PBS-treated mice (P  0.0001). (D) One
intraperitoneal injection of PBS (white bars) or VLP (black bars) was administered to C57Bl/6 mice 3 d before challenge with 100 PFU of
mouse-adapted Ebola virus. Serum was collected from the VLP- or PBSvaccinated mice 4 or 7 d after challenge with Ebola virus and assayed for
viral titers by plaque assay. Data are represented as the mean SD (n 5).

sponses, as mice injected once intraperitoneally with VLPs,
1–3 d before challenge with 3,000 LD50 of Ebola virus
(20) were 80–100% protected from death (Fig. 1 B). However, mice injected 3 d before challenge with either irradiated, inactivated Ebola virus or the sucrose-purified supernatants from mock-transfected cells succumbed to Ebola
virus challenge (Fig. 1 B). Irradiating the VLPs had no ef-

Figure 2. The innate protection against Ebola virus mediated by VLPs
requires functional NK cells. (A) Mediastinal lymph node or splenic cells
from mice injected with VLP (black) or PBS (white) were evaluated for
cell surface expression of NK1.1 by flow cytometry. These data represent
SD. *, P
the mean of the number of NK1.1 cells in each organ
0.001 for the VLP-injected mice compared with the control mice by Student’s paired t test (n 5). Similar results were obtained in two separate
experiments. (B) NK cell–deficient mice (n
6/group) were injected
intraperitoneally with 25 g of VLPs () or media (). As controls,
C57Bl/6 mice (n 6/group) were administered VLPs () or media ().
3 d later, the mice were challenged with 100 PFU of mouse-adapted
Ebola virus. Results are plotted as percent survival for each group. A significant decrease in the survival of VLP-treated NK cell–deficient mice
was observed, as compared with the VLP-treated C57Bl/6 control mice
(P 0.0076). (C) NK cells were depleted from C57Bl/6 mice by intraperitoneal injection of 50 l of anti-asialoGM antibodies every other day
from 5 to 5 d after challenge. Control mice were treated identically
using rabbit Ig (Sigma-Aldrich). NK cell–depleted mice were injected
intraperitoneally with 25 g of VLPs (, n 13) or media (, n 5) 3 d
before challenge or control-treated mice were administered VLPs (, n 5)
or media (, n
5) 3 d before challenge. The mice were challenged
with 100 PFU of mouse-adapted Ebola virus. Percent survival for each
group is shown. A significant difference in the survival of VLP-treated
NK cell–depleted mice was found when compared with the VLP-treated
C57Bl/6 control mice (P 0.0001).
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fect on the outcome of these experiments (unpublished
data), suggesting that the failure of the inactivated Ebola virus to protect mice from Ebola virus infection was not simply due to the irradiation. Intramuscular injection of VLPs
also induced high levels of protection against Ebola virus
challenge (Fig. 1 C), indicating that the route of VLP administration was not linked to protection from Ebola virus
lethality. Circulating Ebola virus was undetectable at 4 or
7 d after Ebola virus challenge in VLP-treated mice, whereas
control mice exhibited high circulating viral titers after
Ebola virus infection (Fig. 1 D). Protection elicited within
1–3 d of VLP injection suggested that VLPs activated innate immune responses. Therefore, this approach gave us a
vital tool to investigate early protective cellular responses to
Ebola virus.
Innate Protection against Ebola Virus Requires NK Cells.
Although many different factors may have contributed to
VLP-induced innate protection, we narrowed our search to
the role of NK cells. Marked increases in NK cell activity
occur early in microbial invasions and result in the recruitment of NK cells to the site of infection (29). VLPs recruited almost twice the number of NK cells in both the
mediastinal lymph node and spleen compared with animals
receiving PBS alone (Fig. 2 A), suggesting that VLP administration induces NK cell proliferation and/or trafficking in
lymphoid tissues. To directly examine the role of NK cells
in Ebola virus infections, NK cell–deficient mice (22) were
administered VLPs 3 d before lethal Ebola virus challenge.
VLP pretreatment of mice lacking functional NK cells did
not protect from Ebola virus infection (Fig. 2 B, 1/6), unlike
VLP-injected wild-type C57Bl/6 mice (6/6, P 0.0076).
Furthermore, mice depleted of NK cells using antiasialoGM1 antibodies were not protected by VLP treatment
(Fig. 2 C, 2/13 survivors), unlike VLP-treated C57Bl/6
0.0001). Although anti-asialomice (14/15 survivors, P
GM1 antibodies can deplete both NK cells and cells of a
monocytic lineage, together these data directly implicated
NK cells in the rapid protection mediated by VLPs.
Because NK cells were required for protection against
Ebola virus infection, we examined whether VLPs induced
the functional activation of NK cells in vitro. To enhance
the number of NK cells and to obtain highly enriched
preparations of NK cells, we used a cDNA hydrodynamic
shearing method (24, 25). After the rapid tail vein injection
of IL-2 plasmid, a substantial increase was observed in the
number of NK cells in the liver (unpublished data). To determine the effect of this procedure on NK cells, we obtained NK cells from livers of untreated or sheared C57Bl/6
mice and found no differences in cytokine profiles when
these cells were stimulated with IL-2, VLPs, or sucrosepurified cell-free supernatants from mock-transfected cells
(Fig. 3 A). The VLPs, but not inactivated Ebola virus, induced IFN- and TNF- secretion from NK cells (Fig. 3,
B and C). NK cells activated with VLPs also secreted IL-4,
IL-5, IL-6, IL-13, and MIP-1, but not detectable IL-2
and IFN- (unpublished data). We performed intracellular
staining for IFN- and surface staining for NK1.1 to con-
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firm that the NK cells were the main producers of IFN-.
There was a considerable increase in the number of
IFN- and NK1.1 cells after VLP stimulation, as compared with NK cells incubated overnight in media alone
(Fig. 3 D). These IFN-, NK1.1 cells did not express
CD3 (unpublished data) and, thus, NK, not NK T, cells
were specifically responsible for IFN- secretion. To show
that this stimulation was the result of VLP preparations and
not endotoxin contamination, VLPs or LPS were boiled or
treated with polymyxin B, a compound that binds and
neutralizes the biological activity of LPS (26), and the preparations were added to purified NK cells. Denaturation of
VLPs by boiling, but not polymyxin B treatment, abrogated the NK cytokine responses; the opposite was true for
LPS (unpublished data). NK cells stimulated with VLPs for
18 h, but not 2 h, specifically killed susceptible YAC-1 target cells (Fig. 3 E). These results show that Ebola VLPs induced strong NK cytotoxic activity, as well as cytokine and
chemokine secretion.
NK Cell Responses to Ebola Virus. Ebola VLPs are morphologically and antigenically similar to live Ebola virus
(Fig. 1 A and references 18, 23, 30). However, unlike
VLPs, inactivated Ebola virus did not induce innate protection from Ebola virus infection or stimulate NK cell responses in vitro (Fig. 1 B). Therefore, we set out to determine if murine NK cells possessed the ability to respond to
live Ebola virus. Unlike exposure to IL-2 or VLPs, live
Ebola virus did not induce secretion of IFN-, MIP-1, or
TNF- from NK cells (Fig. 4, A–C).

Figure 3. Ebola VLPs activate NK cells. (A) NK cells from the livers of
unelicited or IL-2–elicited C57Bl/6 mice were incubated overnight with
10 g of cell-free supernatants from pWRG vector-transfected cells purified on sucrose gradients (white bars, designated pWRG), 100 iU/ml of
mouse IL-2 (gray bars), or 10 g of VLP (black bars). The supernatants
were assayed for IFN- by cytometric bead assay. (B and C) NK from the
livers of IL-2–elicited C57Bl/6 mice were incubated overnight with media
alone, IL-2, or increasing concentrations (0.5–50 g) of VLPs or inactivated Ebola virus. The supernatants were assayed for (B) IFN- or (C)
TNF-. (D) NK cell preparations stimulated overnight with media or
10 g of VLPs. The treated NK cells were stained for surface expression
of NK1.1 and fixed, permeabilized, and stained for intracellular IFN-.
The percent of viable lymphocytes (based on forward and side scatter),
which were positive for both NK1.1 and IFN-, is indicated. The data in
this figure represent three experiments of similar design and outcome.
(E) NK cells were stimulated with VLPs for () 2 h or () 18 h or ()
media alone. After the incubation period, the NK cells were added to
51Cr-labeled YAC-1 cells at varying effector/target ratios as indicated.
The amount of 51Cr released into the supernatant was determined, and
the percent specific release was calculated. Data are representative of at
least two independent experiments.
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Figure 4. Ebola virus effects
on murine NK cells. (A–C) The
concentration of IFN- (A),
MIP-1 (B), or TNF- (C) in
cell supernatants of NK cells exposed to 1 moi of Ebola virusZaire 95 () or –mouse adapted
(), 10 g of VLPs (), 100
iU/ml of IL-2 (), or media
alone () was determined over
time using ELISA. (D) Viral titers in murine NK cells exposed
to Ebola virus. Murine NK cells
were infected with 1 moi of Ebola
virus-Zaire 95 () or –mouse
adapted (). As a control,
VeroE6 cells were infected with
1 moi of Ebola virus-Zaire ()
or –mouse adapted (). The
cell-free supernatants were assayed
for growth of Ebola virus using
plaque assay at the indicated
times. The data are presented as
the number of PFU generated
after exposure of 106 NK cells
over time. These data are representative of three similar and
separate experiments.

Several viruses, including human cytomegalovirus, HIV,
and Epstein-Barr virus replicate efficiently in NK cells (31–
34). To determine whether the lack of NK cell responses
to Ebola virus were caused by Ebola virus infection of the
NK cells, we determined the viral titers in supernatants of
murine NK cells exposed to Ebola virus (multiplicity of infection [moi] 1, Zaire 95 or mouse adapted). Ebola virus
did not replicate in NK cells; in fact, the amount of live virus in the supernatants decreased during the 72 h after exposure to virus (Fig. 4 D). The inability of Ebola virus to
replicate in NK cells was not due to death of the NK cells,
as mock-infected and Ebola virus–infected NK cells had
nearly the same viability after 3 d in culture (unpublished
data). As expected, both viruses grew quickly to high titers
in permissive VeroE6 cells (Fig. 4 D and references 19,
20). Neither wild-type Ebola virus–Zaire nor the mouseadapted strain of Ebola virus stimulated cytokine secretion
in NK cells nor replicated efficiently in murine NK cells,
indicating the mouse-adapted Ebola virus does not differ
drastically from the wild-type Ebola virus–Zaire in regards
to the effects on NK cells (Fig. 4, A–C).
NK Cell–mediated Protection against Ebola Virus Is Perforin
Dependent. Collectively, our observations prompted us to
determine whether these functional responses of the VLPexposed NK cells could reconstitute the short-term protection from Ebola virus observed in mice injected with VLPs.
To do this, VLP-treated NK cells were transferred to naive
mice, and the mice were challenged with Ebola virus. Animals treated with NK cells stimulated with a 10-g dose of
VLPs showed high survival rates (14/20, survivors/total) and
even those mice that were treated with NK cells that had
been stimulated with a low dose of VLPs developed enhanced protection against Ebola virus challenge (Fig. 5 A).
In contrast, none of the mice receiving NK cells treated
with either 50 g/ml of inactivated Ebola virus, 10 g/ml
Figure 5. Perforin-dependent protection mediated by NK cells against
Ebola virus. (A) NK cells from IL-2–treated C57Bl/6 mice were incubated overnight with 1 ( , n 5) or 10 g/ml (, n 20) of VLPs,
50 g/ml of inactivated Ebola virus (, n 10), 10 g/ml of polyI:C
(, n 5), or media alone (, n 10). Naive recipient mice were injected
with 5
106 treated NK cells and challenged 6 h later with 10 PFU of
mouse-adapted Ebola virus. The results are presented on Meier-Kaplan
survival curves. By a one-way Fisher’s exact test, transfer of NK cells
treated with 10 g of VLPs, but not 1 g of VLPs or 50 g of inactivated
Ebola virus, significantly increased the proportion of the mice surviving
challenge (P  0.0001) compared with mice receiving media-treated NK
cells. (B) NK cells were isolated from the livers of IL-2–treated mice by
negative selection. These highly enriched NK cell preparations were incubated overnight with () VLPs or () media alone. Alternately, the
NK cell preparation was depleted of NK1.1 cells using magnetic beads,
and this NK cell–depleted ( 90% reduction) population was stimulated
with VLPs ( ). After overnight incubation, the cell populations were
injected into naive recipient mice (n
10/group), and the mice were
challenged 6 h later with 10 PFU of mouse-adapted Ebola virus. The results
are presented as percent survival for each group and the survival curves
were generated using data from two separate experiments with five mice
per group. A significant increase in survival was observed in mice receiving
the VLP-treated NK cells when compared with mice that received mediatreated NK cells (P  0.0001). In contrast, there was not a significant difference in survival between the mice receiving cell preparations depleted
of NK cells and treated with VLPs, when compared with mice receiving
media-treated NK cells (P 0.5891). (C) NK cells were harvested from
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IFN-–deficient (C57Bl/6 background) mice. The NK cells were incubated
overnight with VLPs () or media alone () and transferred to naive
C57Bl/6 mice. As a control, NK cells from C57Bl/6 mice were incubated overnight with VLPs () and transferred to naive recipient C57Bl/6
mice. The recipient mice were challenged with 10 PFU of Ebola virus
and monitored for illness. The results are presented as percent survival for
each group (n
10), and the survival curves were generated using data
from two separate experiments with five treated mice per group. A significant increase in survival was observed in mice receiving the VLP-treated
NK cells isolated from IFN-–deficient or wild-type C57Bl/6 mice (P
0.0007 or 0.0015, respectively) when compared with control mice that
received media-treated NK cells. (D) NK cells were harvested from perforin-deficient (BALB/c background) mice and were incubated overnight
with VLPs () or media alone (). As a control, NK cells from BALB/c
mice were incubated overnight with VLPs (). 5
106 stimulated NK
cells were transferred to naive BALB/c mice by intraperitoneal injection.
The recipient mice were challenged with 10 PFU of Ebola virus and
monitored for illness. The results are presented as percent survival for
each group (n
10), and the survival curves were generated using data
from two separate experiments with five treated mice per group. A significant increase in survival was observed in mice receiving the VLP-treated
NK cells isolated from wild-type BALB/c mice (P 0.0007) when compared with control mice that received media-treated NK cells. However,
mice receiving VLP-treated NK cells from perforin-deficient mice did
not have a significant increase in survival compared with control mice
that received media-treated NK cells (P 0.5000).
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polyI:C, or media alone survived (Fig. 5 A). Mice that failed
to survive, but received VLP-stimulated NK cells, survived
longer after Ebola virus infection than mice administered
unstimulated NK cells (Fig. 5 A). To confirm that the NK
cells, and not another cell type, were required for protection
from Ebola virus infection, NK1.1 cells were depleted
( 90% removed) from the standard NK cell preparation
and the remaining cells in the preparation were transferred
after overnight incubation with VLPs. The preparation containing NK cells, but not the NK1.1 cell–depleted preparation, protected animals from lethal Ebola virus infection
(Fig. 5 B). VLP-stimulated NK cells from IFN-–deficient
mice resulted in a high level of survival (Fig. 5 C), similar to
NK cells from wild-type mice. In contrast, VLP-stimulated
NK cells isolated from perforin-deficient mice did not elicit
protection from Ebola virus infection (Fig. 5 D). Thus, although IFN- conventionally plays a major role in innate
viral infection, this cytokine was apparently not involved in
innate protection against Ebola virus; however, the protection was tightly connected to perforin-dependent cytotoxic
activity of the NK cells treated with VLPs.
Ebola VP40 Is Sufficient to Induce NK Responses. The
Ebola VLPs are enveloped particles, comprised of the GP
and the matrix VP40, that bud from cellular lipid rafts (23).
We sought to determine whether one of these viral components of the VLPs was responsible for the induction of
NK responses. A single mAb against VP40, but not a pool
of three mAbs against GP or irrelevant antibody (anti–
human CD2), was able to block IFN- secretion by the
VLP-stimulated NK cells (Fig. 6 A). Sera from mice vaccinated with VRP-encoding Ebola VP40 blocked IFN- secretion induced by the VLPs, whereas control sera from
mice vaccinated with a VRP encoding the Lassa virus N
had no effect (Fig. 6 A).
To further examine the role of VP40, we took advantage
of the fact that expression of Ebola virus VP40 alone in

Figure 6. Ebola virus VP40 is sufficient to induce NK cell responses.
(A) Antibodies, including either 30 g of an irrelevant monoclonal to
human CD2 (hCD2), a pool of three monoclonals against GP (GP), or a
monoclonal that recognizes VP40 (VP40), 30 l of sera from mice vaccinated with Venezuelan equine encephalitis replicon particles expressing
VP40 (VRP-VP40), or Lassa virus N (VRP-Lassa), were preincubated for
1 h on ice with 10 g of VLPs. Purified NK cells were incubated overnight with the antibody–VLP complexes, and the concentration of IFN-
in the NK cell supernatants was determined. The data are shown as percentage of the control sample (range: 510–829 pg/ml), which was calculated by the following equation: [IFN- secretion with test antibody/
IFN- secretion with control antibody (hCD2)]
100%. The graph
shows the mean of three experiments with errors bars demonstrating the
standard deviation from the mean of the three experiments. *, significant
inhibition (P  0.05) compared with the control culture as determined by

175

Warfield et al.

paired Student’s t test. (B) VLPs, made of GP and VP40, or VLPVP40 containing VP40 alone, were incubated with NK cells overnight, and the levels
of IFN- in the NK cell supernatants were determined. Data are representative of four independent experiments. (C) NK cells were incubated
with VLPs (), VLPVP40 (), or media alone () overnight and added to
51Cr-labeled YAC-1 cells at varying effector/target ratios. The amount of
51Cr released into the supernatant was determined, and the percentage of
specific release was determined. Similar results were obtained in two separate experiments. (D) NK cells were incubated overnight with 10 g/ml
of VLPs (), VLPVP40 (), or media alone (). Naive mice were injected
intraperitoneally with 5 106 of the VLP- or media-treated NK cells and
challenged 6 h later with 10 PFU of mouse-adapted Ebola virus. The results
are presented as percent survival for each group (n 10), and the survival
curves were generated using data from two separate experiments with five
treated mice per group. A significant increase in survival was observed in
0.0027 or
mice receiving the VLP- or VLPVP40-treated NK cells (P
0.0001, respectively) when compared with control mice that received
media-treated NK cells. (E) C57Bl/6 mice were primed with 10 g of
VLPs (), VLPVP40 (), or PBS () 3 d before challenge with 10 PFU of
mouse-adapted Ebola virus. The data are presented as percent survival for
each group (n
10), and the survival curves were generated using data
from two separate experiments with five treated mice per group. A significant increase in the proportion of mice surviving was observed in mice
treated with VLPs (P  0.0001) or VLPVP40 (P  0.0001) when compared
with control mice injected with PBS.

mammalian cells also results in generation of VLPs
(VLPVP40), although with lower efficiency than with expression of both GP and VP40 (35, 36). NK cells stimulated overnight with VLPVP40 secreted cytokines, including
IFN- (Fig. 6 B). Additionally, VLPVP40-treated NK cells
displayed cytotoxic activity against susceptible targets, similar to NK cells treated with VLPs (Fig. 6 C). When NK
cells were stimulated overnight with VLPVP40 and transferred to naive mice, they fully protected mice from lethal
challenge with Ebola virus infection (Fig. 6 D). Additionally, mice administered VLPVP40 3 d before infection with
mouse-adapted Ebola virus were completely protected
from this lethal challenge (Fig. 6 E). These data suggest that
the main viral protein involved in the innate immune responses to VLPs, including the NK-mediated protective effect, is the matrix protein VP40.

Discussion
We have established a model system to examine Ebola
virus pathogenesis using hollow, genome-free VLPs. The
VLPs swiftly induced effective protective immune responses in mice. This innate protection was dependent on
NK cells because NK cell–deficient and NK cell–depleted
mice were not protected from Ebola virus by the VLPs.
NK cells exposed to VLPs secreted proinflammatory cytokines and chemokines and killed susceptible target cells.
Furthermore, the transfer of VLP-activated NK cells was
sufficient to elicit substantial protection against lethal filovirus infection in mice. The mechanism of innate protection
against Ebola virus was not dependent on IFN-, but perforin was required. The protective effect of the VLPinduced NK cell activity was due mainly to the viral matrix
protein VP40.
Functional changes in NK cells were not detected after
exposure to live or inactivated Ebola virus. NK cells did
not secrete cytokines, including IFN-, TNF-, or MIP1, in response to Ebola virus. Similarly, our in vivo studies have suggested that Ebola virus infection of mice or
monkeys does not activate significant NK cell responses
(unpublished data). Ebola virus may actively interfere with
or avoid innate immune responses, including NK responses
(5, 6). Ebola virus GP has been proposed to modulate host
adaptive immune responses (37). However, GP does not
interfere with early innate immune responses, specifically
NK cell responses, in the context of VLPs because protective immune responses are elicited by both VLPs and
VLPVP40. Ebola virus VP35 is the other known immune
modulator and has been identified as an IFN antagonist. In
Ebola virus–infected cells, VP35 blocks phosphorylation
and dimerization of interferon regulatory factor 3, effectively preventing transcription of key antiviral genes (6, 38,
39). Although Ebola virus was not able to replicate efficiently in murine NK cells, it is possible that the virus was
able to bind to, or enter, these cells and interfere with their
response to the viral antigens through VP35 or other viral
proteins. Although the mechanisms are unclear at this time,
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the virulence of Ebola virus may depend on its ability to
evade or down-regulate the innate immune cell responses
to viral infections, especially early responders such as NK
cells. In fact, there is a specific loss of NK cells and a decrease in NK cell function after Ebola virus infection of
primates (references 40, 41 and unpublished data). Together with our current findings, these data indicate a role
for NK cells in the pathogenesis of Ebola virus.
Viral proteins are capable of directly inducing NK cell
responses (29). Filovirus GPs represented the most likely
candidates for interacting with NK cells directly, as the two
other viral proteins known to directly induce NK cell
responses are also GPs. The murine-activating receptor
Ly49H directly recognizes a MCMV-encoded GP m157,
which is an MHC-like molecule (29, 42). The NKp44 and
NKp46 receptors on human NK cells interact with the influenza virus GP hemagglutinin via sialic acid side chains,
leading to the NK cell–mediated lysis of influenza virus–
infected cells (43, 44). In contrast, we found that the viral
matrix protein VP40, and not Ebola virus GP, is critical
and sufficient for the induction of innate, and specifically
NK cell, responses to Ebola virus. Previously, Ebola virus
GP has been presumed to be the only viral protein exposed
on the surface of the virion. However, it is possible that
VP40 is partially exposed on the virus surface. A recent paper indicated that mAb against the Marburg virus VP40
protein are capable of inducing complement-mediated lysis
of infected cells (45). Crystallographic data show that VP40
can form octamers with a central pore, reminiscent of
pore-forming toxins that insert into the plasma membrane
(46). Furthermore, VP40 possesses integral membrane association characteristics and oligomerizes in the rafts of host
cell membranes before driving virus particle formation (47,
48). Therefore, it is possible that VP40 is partially exposed
on the surface of VLPs, and that this might be important
for the stimulatory effect of these particles on innate immune cells. We propose that recognition of VP40 may be
critical for alerting early, innate immune responses, whereas
the immune responses to GP plays a more important role
in the subsequent generation of protective adaptive immune responses.
In contrast to NK cells from wild-type C57Bl/6 mice,
VLP-stimulated NK cells isolated from perforin-deficient
mice failed to protect naive mice from lethal Ebola virus
infection. Perforin-mediated NK cytotoxicity has a wellestablished role in tumor surveillance (49) and has a recognized, but less appreciated, role in viral infections (50, 51).
Our data are in line with previous findings where control
of HSV-1 infection in the eye and MCMV infection in the
spleen of adult mice is mediated via a perforin-dependent
mechanism (50–52). NK cell cytotoxic activity can be directly activated by receptor–ligand interactions or induced
by exposure to cytokines including IFN-/, TNF-, or
IL-12 (11). However, it is not yet clear whether the cytotoxic activity of VLP-stimulated NK cells is a direct effect,
or the result of secondary stimulation mediated by cytokine
production. The production of cytokines such as IFN-/,
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IFN-, and TNF- by NK cells is important for both the
direct and indirect antiviral activity of NK cells (11). Treating NK cells with VLPs induced considerable secretion of
TNF-, IFN-, and other proinflammatory cytokines in
vitro. The cytokine responses to viral antigens was not due
to priming by IL-2 pretreatment of the mice, as NK cells
from the livers of untreated C57Bl/6 mice secreted cytokines in a similar pattern to that secreted by IL-2–treated
mice after exposure to VLPs (Fig. 3 A and not depicted).
However, IFN- does not appear to be essential for the
protective action of VLPs, as cells from IFN- knockout
mice were fully capable of conveying protection.
NK cells are activated through a variety of ligand–receptor interactions (29). NK cells stimulated with VLPs did
not induce changes in the levels of cell surface NK activating or inhibitory receptors, and we were also unable to
identify a specific population of NK cells associated
with the IFN- secretion (unpublished data). Furthermore,
VLP-stimulated NK cells from BALB/c mice secreted cytokines in a similar manner to C57Bl/6 mice and protected
against Ebola virus challenge when transferred to naive
mice (Fig. 5 D and unpublished data). Therefore, VLP
stimulation of NK cells is not restricted to a single mouse
strain, and it is not related to the expression of Ly49H-activating receptor (53). It is possible that NK cell activation
by VLPs may not be receptor-mediated, but may be mediated purely by cytokines or other unidentified mechanisms.
PolyI:C treatment of NK cells significantly increases protection against HSV-1 infection when compared with protection provided by untreated cells (15). In contrast, we
found that polyI:C treatment of NK cells before transfer
did not confer protection from Ebola virus infection (Fig.
5 A), indicating that nonspecific stimulation of NK cells is
not sufficient for protection. In support of these findings,
CpG treatment of the NK cell preparations before transfer
did not protect naive mice from Ebola virus challenge (unpublished data), further suggesting that activation of APCs
in NK cell preparations could not account for the observed
protection. Therefore, the protection provided by VLPtreated NK cells appears to be mediated by VLP-specific
responses, although we do not understand the mechanisms
of action at this time.
We were concerned that NK T cells contributed to the
biological responses of our VLP-exposed cellular preparations. However, the NK cell–enriched preparations did not
contain CD3 NK T cells, but were contaminated with
eosinophils (10%), B220MHC class II cells (3%) that
could be macrophages, DCs or B cells, and a small number
of CD5 T cells (2%). Depletion of NK1.1 cells from
the cell preparations before transfer abrogated innate protection from Ebola virus, suggesting that contaminating
APCs, eosinophils, or other lymphocytes were not required for innate responses to Ebola virus. Nonetheless, it
may be that VLPs are taken up by DCs or macrophages,
which in turn activate the NK cells or that VLPs are rapidly
processed and presented by the APCs to B or T cells. In
contrast, exposure to inactivated Ebola virus does not acti177
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vate or mature murine DCs (18) and, thus, likely does not
efficiently prime secondary lymphocyte responses. We
have shown previously that both B and T lymphocytes are
activated transiently 2–3 d after challenge in the lymph
nodes of VLP-vaccinated mice (18). Changes in early T
cell activation markers, including CD25, CD43, and
CD69, are not detectable until at least 48 h after injection
in lymph nodes, spleen, or peritoneal cavity and, thus, do
not exactly correlate with the rapid protection observed in
our current work within 1 d after injection (reference 18
and unpublished data). In this paper, we have shown a critical involvement of NK cells in innate protection against
Ebola virus infection; however, at this time, we cannot rule
out the contribution of other cell types, including DCs, B,
and T cells.
The innate immune system provides early surveillance
and control of viral infections. In this paper, we show that
the innate immune response, specifically NK cells, can mediate rapid and complete protection against lethal Ebola virus infection. These observations represent a key advance
in understanding the requirements for protective immunity
against Ebola virus infection. The identification of NK cells
as critical mediators of early protection against Ebola virus
infection are an important step forward in the identification
of prophylactic and therapeutic interventions against filovirus and other incapacitating acute viral infections. Although the exact application of these findings to therapeutics in treating Ebola virus–infected primates and humans is
unclear at this time, therapeutic agents that bolster the innate immune response, including activation of NK cells,
should be the target of future studies.
We thank G. Ruthel and M. Thompson for their help in generating the AFM image; M.K. Hart for providing mouse antisera; T.
Sayers for the perforin-deficient mice; J. Wine, D. Reynolds, M.
Orihuela, and M. Gibson for animal coordination and handling; S.
Norris for statistical analysis; and A. Schmaljohn, J. Ortaldo, and D.
McVicar for helpful discussions.
K.L. Warfield and D.L. Swenson are both the recipients of National Research Council Fellowships. This work was sponsored by
the Medical Research and Material Command Research Plan (no.
03-4-7J-021).
Submitted: 10 December 2003
Accepted: 9 June 2004

References
1. Feldmann, H., W. Slenczka, and H.D. Klenk. 1996. Emerging
and reemerging of filoviruses. Arch. Virol. Suppl. 11:77–100.
2. Feldmann, H., S. Jones, H.D. Klenk, and H.J. Schnittler.
2003. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol. 3:677–685.
3. Johnson, E., N. Jaax, J. White, and P. Jahrling. 1995. Lethal
experimental infections of rhesus monkeys by aerosolized
Ebola virus. Int. J. Exp. Pathol. 76:227–236.
4. Stroher, U., E. West, H. Bugany, H.D. Klenk, H.J. Schnittler,
and H. Feldmann. 2001. Infection and activation of monocytes
by Marburg and Ebola viruses. J. Virol. 75:11025–11033.
5. Mahanty, S., K. Hutchinson, S. Agarwal, M. McRae, P.E.

6.

7.

8.

9.

10.

11.

12.
13.
14.
15.

16.
17.
18.

19.

20.
21.

Rollin, and B. Pulendran. 2003. Cutting edge: impairment of
dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170:2797–2801.
Bosio, C.M., M.J. Aman, C. Grogan, R. Hogan, G. Ruthel,
D. Negley, M. Mohamadzadeh, S. Bavari, and A. Schmaljohn.
2003. Ebola and Marburg viruses replicate in monocytederived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 188:1630–1638.
Baize, S., E.M. Leroy, M.C. Georges-Courbot, M. Capron,
J. Lansoud-Soukate, P. Debre, S.P. Fisher-Hoch, J.B. McCormick, and A.J. Georges. 1999. Defective humoral responses and extensive intravascular apoptosis are associated
with fatal outcome in Ebola virus-infected patients. Nat. Med.
5:423–426.
Leroy, E.M., S. Baize, V.E. Volchkov, S.P. Fisher-Hoch,
M.C. Georges-Courbot, J. Lansoud-Soukate, M. Capron, P.
Debre, J.B. McCormick, and A.J. Georges. 2000. Human
asymptomatic Ebola infection and strong inflammatory response. Lancet. 355:2210–2215.
Leroy, E.M., S. Baize, P. Debre, J. Lansoud-Soukate, and E.
Mavoungou. 2001. Early immune responses accompanying
human asymptomatic Ebola infections. Clin. Exp. Immunol.
124:453–460.
Baize, S., E.M. Leroy, A.J. Georges, M.C. Georges-Courbot,
M. Capron, I. Bedjabaga, J. Lansoud-Soukate, and E. Mavoungou. 2002. Inflammatory responses in Ebola virusinfected patients. Clin. Exp. Immunol. 128:163–168.
Biron, C.A., K.B. Nguyen, G.C. Pien, L.P. Cousens, and
T.P. Salazar-Mather. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu.
Rev. Immunol. 17:189–220.
Guidotti, L.G., and F.V. Chisari. 2001. Noncytolytic control
of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19:65–91.
Lieberman, L.A., and C.A. Hunter. 2002. Regulatory pathways involved in the infection-induced production of IFNgamma by NK cells. Microbes Infect. 4:1531–1538.
Scalzo, A.A. 2002. Successful control of viruses by NK cells–
a balance of opposing forces? Trends Microbiol. 10:470–474.
Rager-Zisman, B., P.C. Quan, M. Rosner, J.R. Moller, and
B.R. Bloom. 1987. Role of NK cells in protection of mice
against herpes simplex virus-1 infection. J. Immunol. 138:
884–888.
Bukowski, J.F., J.F. Warner, G. Dennert, and R.M. Welsh.
1985. Adoptive transfer studies demonstrating the antiviral
effect of natural killer cells in vivo. J. Exp. Med. 161:40–52.
Biron, C.A., K.S. Byron, and J.L. Sullivan. 1989. Severe herpesvirus infections in an adolescent without natural killer
cells. N. Engl. J. Med. 320:1731–1735.
Warfield, K.L., C.M. Bosio, B.C. Welcher, E.M. Deal, M.
Mohamadzadeh, A. Schmaljohn, M.J. Aman, and S. Bavari.
2003. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. USA. 100:15889–15894.
Jahrling, P.B., J. Geisbert, J.R. Swearengen, G.P. Jaax, T.
Lewis, J.W. Huggins, J.J. Schmidt, J.W. LeDuc, and C.J. Peters. 1996. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune
horses. Arch. Virol. Suppl. 11:135–140.
Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins.
1999. A mouse model for evaluation of prophylaxis and therapy
of Ebola hemorrhagic fever. J. Infect. Dis. 179:S248–S258.
Hevey, M., D. Negley, J. Geisbert, P. Jahrling, and A.
Schmaljohn. 1997. Antigenicity and vaccine potential of

178

22.

23.

24.
25.

26.
27.

28.
29.
30.

31.

32.

33.

34.
35.
36.

37.

Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 239:206–216.
Kim, S., K. Iizuka, H.L. Aguila, I.L. Weissman, and W.M.
Yokoyama. 2000. In vivo natural killer cell activities revealed
by natural killer cell-deficient mice. Proc. Natl. Acad. Sci.
USA. 97:2731–2736.
Bavari, S., C.M. Bosio, E. Wiegand, G. Ruthel, A.B. Will,
T.W. Geisbert, M. Hevey, C. Schmaljohn, A. Schmaljohn,
and M.J. Aman. 2002. Lipid raft microdomains: a gateway for
compartmentalized trafficking of Ebola and Marburg viruses.
J. Exp. Med. 195:593–602.
Liu, F., Y. Song, and D. Liu. 1999. Hydrodynamics-based
transfection in animals by systemic administration of plasmid
DNA. Gene Ther. 6:1258–1266.
He, Y., A.A. Pimenov, J.V. Nayak, J. Plowey, L.D. Falo, Jr.,
and L. Huang. 2000. Intravenous injection of naked DNA
encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum.
Gene Ther. 11:547–554.
Jacobs, D.M., and D.C. Morrison. 1977. Inhibition of the
mitogenic response to lipopolysaccharide (LPS) in mouse
spleen cells by polymyxin B. J. Immunol. 118:21–27.
Wilson, J.A., M. Hevey, R. Bakken, S. Guest, M. Bray, A.L.
Schmaljohn, and M.K. Hart. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 287:
1664–1666.
Wilson, J.A., M. Bray, R. Bakken, and M.K. Hart. 2001.
Vaccine potential of Ebola virus VP24, VP30, VP35, and
VP40 proteins. Virology. 286:384–390.
Yokoyama, W.M., and A.A. Scalzo. 2002. Natural killer cell
activation receptors in innate immunity to infection. Microbes
Infect. 4:1513–1521.
Swenson, D.L., K.L. Warfield, K. Kuehl, T. Larsen, M.C.
Hevey, A. Schmaljohn, S. Bavari, and M.J. Aman. 2004.
Generation of Marburg virus-like particles by co-expression
of glycoprotein and matrix protein. FEMS Immunol. Med.
Microbiol. 40:27–31.
Rice, G.P., R.D. Schrier, and M.B. Oldstone. 1984. Cytomegalovirus infects human lymphocytes and monocytes:
virus expression is restricted to immediate-early gene products. Proc. Natl. Acad. Sci. USA. 81:6134–6138.
Chehimi, J., S. Bandyopadhyay, K. Prakash, B. Perussia, N.F.
Hassan, H. Kawashima, D. Campbell, J. Kornbluth, and S.E.
Starr. 1991. In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates. J. Virol.
65:1812–1822.
Kanegane, H., K. Nomura, T. Miyawaki, and G. Tosato.
2002. Biological aspects of Epstein-Barr virus (EBV)-infected
lymphocytes in chronic active EBV infection and associated
malignancies. Crit. Rev. Oncol. Hematol. 44:239–249.
Valentin, A., and G.N. Pavlakis. 2003. Natural killer cells are
persistently infected and resistant to direct killing by HIV-1.
Anticancer Res. 23:2071–2075.
Timmins, J., S. Scianimanico, G. Schoehn, and W. Weissenhorn. 2001. Vesicular release of ebola virus matrix protein
VP40. Virology. 283:1–6.
Noda, T., H. Sagara, E. Suzuki, A. Takada, H. Kida, and Y.
Kawaoka. 2002. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J. Virol. 76:
4855–4865.
Feldmann, H., V.E. Volchkov, V.A. Volchkova, and H.D.
Klenk. 1999. The glycoproteins of Marburg and Ebola virus
and their potential roles in pathogenesis. Arch. Virol. Suppl.

NK Cells Protect against Lethal Ebola Virus Infection

15:159–169.
38. Basler, C.F., X. Wang, E. Muhlberger, V. Volchkov, J. Paragas, H.D. Klenk, A. Garcia-Sastre, and P. Palese. 2000. The
Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. USA. 97:12289–12294.
39. Basler, C.F., A. Mikulasova, L. Martinez-Sobrido, J. Paragas,
E. Muhlberger, M. Bray, H.D. Klenk, P. Palese, and A. Garcia-Sastre. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77:7945–7956.
40. Ignatiev, G.M., A.A. Dadaeva, S.V. Luchko, and A.A. Chepurnov. 2000. Immune and pathophysiological processes in
baboons experimentally infected with Ebola virus adapted to
guinea pigs. Immunol. Lett. 71:131–140.
41. Geisbert, T.W., L.E. Hensley, T. Larsen, H.A. Young, D.S.
Reed, J.B. Geisbert, D.P. Scott, E. Kagan, P.B. Jahrling, and
K.J. Davis. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and
sustained targets of infection. Am. J. Pathol. 163:2347–2370.
42. Arase, H., E.S. Mocarski, A.E. Campbell, A.B. Hill, and L.L.
Lanier. 2002. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science. 296:1323–1326.
43. Mandelboim, O., N. Lieberman, M. Lev, L. Paul, T.I. Arnon, Y. Bushkin, D.M. Davis, J.L. Strominger, J.W. Yewdell, and A. Porgador. 2001. Recognition of haemagglutinins
on virus-infected cells by NKp46 activates lysis by human
NK cells. Nature. 409:1055–1060.
44. Arnon, T.I., M. Lev, G. Katz, Y. Chernobrov, A. Porgador,
and O. Mandelboim. 2001. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur. J. Immunol. 31:
2680–2689.
45. Razumov, I.A., E.F. Belanov, A.A. Bukreev, and E.I. Kazachinkskaia. 1998. Monoclonal antibodies to Marburg virus
proteins and their immunochemical characteristics. [In Rus-

179

Warfield et al.

sian.] Vopr. Virusol. 43:274–279.
46. Gomis-Ruth, F.X., A. Dessen, J. Timmins, A. Bracher, L.
Kolesnikowa, S. Becker, H.D. Klenk, and W. Weissenhorn.
2003. The matrix protein VP40 from Ebola virus octamerizes
into pore-like structures with specific RNA binding properties. Structure (Camb). 11:423–433.
47. Panchal, R.G., G. Ruthel, T.A. Kenny, G.H. Kallstrom, D.
Lane, S.S. Badie, L. Li, S. Bavari, and M.J. Aman. 2003. In
vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc. Natl. Acad. Sci.
USA. 100:15936–15941.
48. Jasenosky, L.D., G. Neumann, I. Lukashevich, and Y.
Kawaoka. 2001. Ebola virus VP40-induced particle formation
and association with the lipid bilayer. J. Virol. 75:5205–5214.
49. van den Broek, M.F., and H. Hengartner. 2000. The role of
perforin in infections and tumour surveillance. Exp. Physiol.
85:681–685.
50. Ghiasi, H., S. Cai, G. Perng, A.B. Nesburn, and S.L. Wechsler. 1999. Perforin pathway is essential for protection of
mice against lethal ocular HSV-1 challenge but not corneal
scarring. Virus Res. 65:97–101.
51. Tay, C.H., and R.M. Welsh. 1997. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus
infection by natural killer cells. J. Virol. 71:267–275.
52. Tay, C.H., L.Y. Yu, V. Kumar, L. Mason, J.R. Ortaldo, and
R.M. Welsh. 1999. The role of LY49 NK cell subsets in the
regulation of murine cytomegalovirus infections. J. Immunol.
162:718–726.
53. Brown, M.G., A.O. Dokun, J.W. Heusel, H.R. Smith, D.L.
Beckman, E.A. Blattenberger, C.E. Dubbelde, L.R. Stone,
A.A. Scalzo, and W.M. Yokoyama. 2001. Vital involvement
of a natural killer cell activation receptor in resistance to viral
infection. Science. 292:934–937.

